Diabetes mellitus type 1 screening: Difference between revisions
No edit summary |
No edit summary |
||
Line 47: | Line 47: | ||
|Not determined | |Not determined | ||
|} | |} | ||
<sub> | <sub><big>* TEDDY (The Environmental Determinants of [[Diabetes]] in the Young) study reported higher [[c-peptide]] level at least within 12 months after [[diagnosis]], which is related to better response to [[immunology|immunologic]] interventions</big>.<ref name="pmid28127835">{{cite journal| author=Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA | display-authors=etal| title=Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. | journal=Pediatr Diabetes | year= 2017 | volume= 18 | issue= 8 | pages= 794-802 | pmid=28127835 | doi=10.1111/pedi.12485 | pmc=5529265 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28127835 }}</ref></big></sub> | ||
<sub><big>* DIPP (Finnish [[Type 1 diabetes]] Prediction and [[Prevention (medical)|Prevention]]) reported lower rate of [[weight loss]] among [[patient|patients]] who were screened for [[diabetes mellitus type 1]]<ref name="pmid30426167">{{cite journal| author=Narendran P| title=Screening for type 1 diabetes: are we nearly there yet? | journal=Diabetologia | year= 2019 | volume= 62 | issue= 1 | pages= 24-27 | pmid=30426167 | doi=10.1007/s00125-018-4774-0 | pmc=6290651 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30426167 }} </ref></big></sub> | |||
Revision as of 18:25, 11 September 2020
Diabetes mellitus type 1 Microchapters |
Differentiating Diabetes mellitus type 1 from other Diseases |
Diagnosis |
Treatment |
Cardiovascular Disease and Risk Management |
Case Studies |
Diabetes mellitus Main page |
Patient Information |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]
Overview
According to the American Diabetic Association, screening for type 1 DM is not recommended.[1]
Screening
- According to the American diabetic association screening for type 1 DM is not recommended. However, one should consider referring relatives of those with type 1 diabetes for antibody testing for risk assessment in the setting of a clinical research. Higher-risk individuals may be tested, but only in the context of a clinical research setting.[1]
- Based on some studies, screening for diabetic patients has some favorable effects. The following table is a summary of screening effects based on 6 pediatric studies:[2][3][4][5][6][7]
Study | Less DKA | Lower HbA1c | Lower insulin dose | Shorter hospitalization period |
---|---|---|---|---|
BABYDIAB and Munich | + | + | - | + |
DiPiS | + | + | - | Not determined |
TEDDY | + | + | + | Not determined |
DAISY | + | + | + | + |
DIPP | + | + | Not determined | Not determined |
* TEDDY (The Environmental Determinants of Diabetes in the Young) study reported higher c-peptide level at least within 12 months after diagnosis, which is related to better response to immunologic interventions.[5] * DIPP (Finnish Type 1 diabetes Prediction and Prevention) reported lower rate of weight loss among patients who were screened for diabetes mellitus type 1[8]
References
- ↑ 1.0 1.1 http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf
- ↑ Winkler C, Schober E, Ziegler AG, Holl RW (2012). "Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies". Pediatr Diabetes. 13 (4): 308–13. doi:10.1111/j.1399-5448.2011.00829.x. PMID 22060727.
- ↑ Elding Larsson H, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C; et al. (2011). "Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up". Diabetes Care. 34 (11): 2347–52. doi:10.2337/dc11-1026. PMC 3198296. PMID 21972409.
- ↑ Lundgren M, Sahlin Å, Svensson C, Carlsson A, Cedervall E, Jönsson B; et al. (2014). "Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up". Pediatr Diabetes. 15 (7): 494–501. doi:10.1111/pedi.12151. PMC 4190091. PMID 24823816.
- ↑ 5.0 5.1 Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA; et al. (2017). "Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls". Pediatr Diabetes. 18 (8): 794–802. doi:10.1111/pedi.12485. PMC 5529265. PMID 28127835.
- ↑ Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hämäläinen AM; et al. (2001). "Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort". Diabetologia. 44 (3): 290–7. doi:10.1007/s001250051616. PMID 11317658.
- ↑ Hekkala AM, Ilonen J, Toppari J, Knip M, Veijola R (2018). "Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children". Pediatr Diabetes. 19 (2): 314–319. doi:10.1111/pedi.12541. PMID 28544185.
- ↑ Narendran P (2019). "Screening for type 1 diabetes: are we nearly there yet?". Diabetologia. 62 (1): 24–27. doi:10.1007/s00125-018-4774-0. PMC 6290651. PMID 30426167.